Streetbeat News

Earnings

RDCM

Radcom (NASDAQ:RDCM) reported Q3 earnings of $0.15 per share, beating the analyst consensus estimate of $0.09 by 66.67%. This is a 150% increase from the same period last year. The company also reported quarterly sales of $13.20 million, beating the analyst consensus estimate of $12.72 million by 3.73%, a 9.86% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 12:11 pm

REYN

Reynolds Consumer Products has revised its FY23 net revenues outlook from +/-1% to -2%, and its EPS outlook from $1.34-$1.41 to $1.37-$1.41.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 12:10 pm

SPTN

SpartanNash has revised its FY23 adjusted EPS guidance from $2.20 - $2.35 to $2.20 - $2.28, which is in line with the estimated $2.26.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 12:10 pm

HGTY

Hagerty (NYSE:HGTY) reported Q3 earnings of $0.05 per share, missing the analyst consensus estimate of $0.06 by 16.67%. However, the company's quarterly sales of $275.57 million beat the analyst consensus estimate of $269.43 million by 2.28%. This represents a 183.33% increase in earnings and a 27.13% increase in sales compared to the same period last year.

Portfolio Pulse from saritha@benzinga.com

November 08, 2023 | 12:10 pm

PYPD

PolyPid (NASDAQ:PYPD) reported Q3 losses of $(3.40) per share, beating the analyst consensus estimate of $(4.16) by 18.27%. This is a 76.39% increase over losses from the same period last year. The company had cash and cash equivalents and deposits of $10.2 million as of September 30, 2023, which is expected to fund operations into late Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 12:10 pm

LXRX

Lexicon Pharmaceuticals reported Q3 GAAP EPS of $(0.21), in line with analyst consensus. However, the company's sales of $162.00K missed the estimate of $2.06M by 92.14%. This represents a 61.54% decrease in losses from the same period last year and a 315.38% increase in sales from the same period last year. The company's cash and investments stand at $218.4M.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 12:10 pm

FOLD

Amicus Therapeutics reported Q3 earnings per share (EPS) of $(0.07), beating the analyst consensus estimate of $(0.08) by 12.5%. This is a 41.67% increase over the same period last year. The company also reported quarterly sales of $103.50 million, beating the analyst consensus estimate of $101.36 million by 2.11%. This is a 26.70% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 12:10 pm

INVZ

Innoviz Technologies reported its Q3 earnings per share (EPS) at $(0.18), an improvement from $(0.25) year over year (YoY). The company's sales also beat estimates, coming in at $3.48 million against the estimated $3.00 million.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 12:10 pm

VERI

Veritone reported Q3 adjusted losses of $(0.21) per share, missing the analyst consensus estimate of $(0.18) by 16.67%. The company's quarterly sales were $35.13 million, missing the estimate of $35.86 million by 2.03%. This represents a 31.25% decrease in losses and a 5.55% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 12:09 pm

STER

Sterling Check (NASDAQ:STER) reported Q3 2023 earnings of $0.26 per share, missing the analyst consensus estimate of $0.30 by 13.33%. The company also reported quarterly sales of $180.57 million, missing the analyst consensus estimate of $193.51 million by 6.69%. Both earnings and sales show a decrease compared to the same period last year.

Portfolio Pulse from saritha@benzinga.com

November 08, 2023 | 12:09 pm